Deze keuzehulp is gebaseerd op de Handleiding behandeling IBD voor volwassenen (versie 2014) van het Initiatief in Crohn en Colitis (ICC) en de Nederlandse Vereniging van Maag-, Darm- en Leverartsen (NVMDL).
Ook zijn de volgende bronnen gebruikt:
- Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2016;375:1946-1960. Hier te vinden
- Sandborn WJ, Rebuck R, Wang Y, et al. Five-year efficacy and safety of ustekinumab treatment in Crohn’s disease: the IM-UNITI trial. Clin Gastroenterol Hepatol 2022;20:578-590. Hier te vinden
- Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013;369:711-721. Hier te vinden
- Vermeire S, Loftus Jr EV, Colombel JF, et al. Long-term efficacy of vedolizumab for Crohn’s disease. J Crohn Colitis 2017;11:412-424. Hier te vinden
- Sulz MC, Burri E, Michetti P, et al. Treatment algorithms for Crohn’s disease. Digestion 2020;101:43-57. Hier te vinden
- Stevens TW, Haasnoot ML, D’Haens GR, et al. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: retrospective long-term follow-up of the LIR!C trial. Lancet Gastroenterol Hepatol 2020;5:900-907. Hier te vinden
- Eshuis EJ, Peters CP, Van Bodegraven AA, et al. Ten years of infliximab for Crohn’s disease: outcome in 469 patients from 2 tertiary referral centers. Inflamm Bowel Dis 2013;19:1622-1630. Hier te vinden
- Atreya R, Bojarski C, Kühl AA, et al. Ileal and colonic Crohn’s disease: does location make a difference in therapy efficacy? Curr Res Pharmacol Drug Discov 2022;3:100097. Hier te vinden
- Peters CP, Eshuis EJ, Toxopeüs FM, et al. Adalimumab for Crohn’s disease: Long-term sustained benefit in a population-based cohort of 438 patients. J Crohns Colitis 2014;8:866-875. Hier te vinden
- Townsend CM, Nguyen TM, Cepek J, et al. Adalimumab for maintenance of remission in Crohn’s disease. Cochrane Datab Syst Rev 2020;5:CD012877. Hier te vinden
- Ponsioen CY, de Groof EJ, Eshuis EJ, et al. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: a randomized controlled, open-label, multicentre trial. Lancet Gastroenterol Hepatol 2017;2:785-792. Hier te vinden
- Riss S, Bittermann C, Schwameis K, et al. Determinants for postoperative complications after laparoscopic intestinal resection for Crohn’s disease. Surg Endosc 2012;26:933-938. Hier te vinden